XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual
N/A
USD
N/A
N/A
...
Chart
Financials
Description
XOMAP Company Description
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
XOMAP Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view XOMAP Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of XOMAP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by XOMAP's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of XOMAP in WallStreetBets Daily Discussion
XOMAP News
Recent insights relating to XOMAP
CNBC Recommendations
Recent picks made for XOMAP stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in XOMAP
Corporate Flights
Flights by private jets registered to XOMAP
Our Analysis